JP4043953B2 - mGluR2アンタゴニストIとしてのジヒドロ−ベンゾ〔b〕〔1,4〕ジアゼピン−2−オン誘導体 - Google Patents

mGluR2アンタゴニストIとしてのジヒドロ−ベンゾ〔b〕〔1,4〕ジアゼピン−2−オン誘導体 Download PDF

Info

Publication number
JP4043953B2
JP4043953B2 JP2002581420A JP2002581420A JP4043953B2 JP 4043953 B2 JP4043953 B2 JP 4043953B2 JP 2002581420 A JP2002581420 A JP 2002581420A JP 2002581420 A JP2002581420 A JP 2002581420A JP 4043953 B2 JP4043953 B2 JP 4043953B2
Authority
JP
Japan
Prior art keywords
phenyl
dihydro
benzo
diazepin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002581420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525965A (ja
JP2004525965A5 (cg-RX-API-DMAC7.html
Inventor
アダム,ゲオ
ゲッチ,エルヴィン
ミュッテル,ヴァンサン
ヴィッヒマン,ユルゲン
ヴォルテリング,トーマス・ヨハネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004525965A publication Critical patent/JP2004525965A/ja
Publication of JP2004525965A5 publication Critical patent/JP2004525965A5/ja
Application granted granted Critical
Publication of JP4043953B2 publication Critical patent/JP4043953B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2002581420A 2001-04-12 2002-04-02 mGluR2アンタゴニストIとしてのジヒドロ−ベンゾ〔b〕〔1,4〕ジアゼピン−2−オン誘導体 Expired - Fee Related JP4043953B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12
PCT/EP2002/003643 WO2002083665A1 (en) 2001-04-12 2002-04-02 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I

Publications (3)

Publication Number Publication Date
JP2004525965A JP2004525965A (ja) 2004-08-26
JP2004525965A5 JP2004525965A5 (cg-RX-API-DMAC7.html) 2005-07-28
JP4043953B2 true JP4043953B2 (ja) 2008-02-06

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002581420A Expired - Fee Related JP4043953B2 (ja) 2001-04-12 2002-04-02 mGluR2アンタゴニストIとしてのジヒドロ−ベンゾ〔b〕〔1,4〕ジアゼピン−2−オン誘導体

Country Status (37)

Country Link
US (1) US6548495B2 (cg-RX-API-DMAC7.html)
EP (1) EP1379522B1 (cg-RX-API-DMAC7.html)
JP (1) JP4043953B2 (cg-RX-API-DMAC7.html)
KR (1) KR100566178B1 (cg-RX-API-DMAC7.html)
CN (1) CN1268626C (cg-RX-API-DMAC7.html)
AR (1) AR035456A1 (cg-RX-API-DMAC7.html)
AT (1) ATE287883T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002310912B2 (cg-RX-API-DMAC7.html)
BG (1) BG108253A (cg-RX-API-DMAC7.html)
BR (1) BR0208887A (cg-RX-API-DMAC7.html)
CA (1) CA2441771C (cg-RX-API-DMAC7.html)
CZ (1) CZ20033002A3 (cg-RX-API-DMAC7.html)
DE (1) DE60202761T2 (cg-RX-API-DMAC7.html)
DK (1) DK1379522T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034796A (cg-RX-API-DMAC7.html)
ES (1) ES2235044T3 (cg-RX-API-DMAC7.html)
GT (1) GT200200072A (cg-RX-API-DMAC7.html)
HR (1) HRP20030791B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0400991A3 (cg-RX-API-DMAC7.html)
IL (2) IL158021A0 (cg-RX-API-DMAC7.html)
JO (1) JO2273B1 (cg-RX-API-DMAC7.html)
MA (1) MA27011A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03009317A (cg-RX-API-DMAC7.html)
MY (1) MY130369A (cg-RX-API-DMAC7.html)
NO (1) NO325300B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ528345A (cg-RX-API-DMAC7.html)
PA (1) PA8543201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20021072A1 (cg-RX-API-DMAC7.html)
PL (1) PL367086A1 (cg-RX-API-DMAC7.html)
PT (1) PT1379522E (cg-RX-API-DMAC7.html)
RU (1) RU2270197C2 (cg-RX-API-DMAC7.html)
SI (1) SI1379522T1 (cg-RX-API-DMAC7.html)
SK (1) SK13692003A3 (cg-RX-API-DMAC7.html)
UY (1) UY27259A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002083665A1 (cg-RX-API-DMAC7.html)
YU (1) YU79103A (cg-RX-API-DMAC7.html)
ZA (1) ZA200307242B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386980C (en) * 1999-10-15 2010-03-16 Geo Adam Benzodiazepine derivatives for use in acute or chronic neurological disorders
RU2357734C2 (ru) * 2003-07-25 2009-06-10 Ф.Хоффманн-Ля Рош Аг КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА mGluR2 И ИНГИБИТОРА ФЕРМЕНТА AChE ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И/ИЛИ ХРОНИЧЕСКИХ НЕВРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ
ES2309814T3 (es) 2004-11-05 2008-12-16 F. Hoffmann-La Roche Ag Proceso para la obtencion de derivados del acido isonicotinico.
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
KR101151993B1 (ko) * 2007-04-19 2012-06-01 에프. 호프만-라 로슈 아게 다이하이드로-벤조[b][1,4]다이아제핀-2-온 설폰아미드 유도체
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
WO2009033703A1 (en) * 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
RS51660B (sr) 2007-09-14 2011-10-31 Ortho-Mcneil-Janssen Pharmaceuticals Inc. 1`,3`-disupstituisani-4-fenil-3,4,5,6-tetrahidro-2h, 1`h-[1,4`] bipiridinil-2`-oni
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
KR20120035158A (ko) 2009-05-12 2012-04-13 얀센 파마슈티칼즈, 인코포레이티드 1,2,4?트리아졸로[4,3?a]피리딘 유도체 및 mGluR2 수용체의 양성 알로스테릭 조절자로서의 그의 용도
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
EP2925292A1 (en) 2012-10-23 2015-10-07 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of autistic disorders
RS57602B1 (sr) * 2013-02-28 2018-11-30 Eisai R&D Man Co Ltd Derivat tetrahidroimidazo[1,5-d][1,4]oksazepina
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CN109999033B (zh) 2014-01-21 2022-12-23 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
HRP20191646T1 (hr) 2014-01-21 2019-12-13 Janssen Pharmaceutica Nv Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba
CA2943877A1 (en) 2014-04-23 2015-10-29 F. Hoffmann-La Roche Ag Mglu2/3 antagonists for the treatment of intellectual disabilities
WO2015191630A1 (en) * 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
AU6420700A (en) * 1999-08-05 2001-03-05 Prescient Neuropharma Inc. Novel 1,4-benzodiazepine compounds and derivatives thereof
CN1195522C (zh) * 1999-10-15 2005-04-06 弗·哈夫曼-拉罗切有限公司 苯并二氮杂䓬衍生物
CA2386980C (en) * 1999-10-15 2010-03-16 Geo Adam Benzodiazepine derivatives for use in acute or chronic neurological disorders

Also Published As

Publication number Publication date
YU79103A (sh) 2006-05-25
EP1379522A1 (en) 2004-01-14
DE60202761T2 (de) 2006-01-12
CA2441771C (en) 2008-12-30
IL158021A0 (en) 2004-03-28
WO2002083665A1 (en) 2002-10-24
SK13692003A3 (sk) 2004-05-04
PE20021072A1 (es) 2002-12-07
JO2273B1 (en) 2005-04-07
CN1522252A (zh) 2004-08-18
AR035456A1 (es) 2004-05-26
MA27011A1 (fr) 2004-12-20
EP1379522B1 (en) 2005-01-26
HRP20030791A2 (en) 2005-06-30
DE60202761D1 (de) 2005-03-03
MXPA03009317A (es) 2004-02-12
ECSP034796A (es) 2003-12-01
IL158021A (en) 2010-04-15
UY27259A1 (es) 2002-10-31
NO20034496L (no) 2003-10-08
PL367086A1 (en) 2005-02-21
JP2004525965A (ja) 2004-08-26
KR20030088502A (ko) 2003-11-19
BG108253A (bg) 2005-03-31
PA8543201A1 (es) 2002-10-31
ZA200307242B (en) 2004-12-16
RU2003130648A (ru) 2005-04-10
HK1068339A1 (en) 2005-04-29
CZ20033002A3 (cs) 2004-03-17
MY130369A (en) 2007-06-29
ATE287883T1 (de) 2005-02-15
HUP0400991A2 (hu) 2004-08-30
US20020198197A1 (en) 2002-12-26
HRP20030791B1 (en) 2006-06-30
CA2441771A1 (en) 2002-10-24
US6548495B2 (en) 2003-04-15
BR0208887A (pt) 2004-06-29
KR100566178B1 (ko) 2006-03-29
CN1268626C (zh) 2006-08-09
PT1379522E (pt) 2005-05-31
GT200200072A (es) 2003-06-19
SI1379522T1 (en) 2005-04-30
ES2235044T3 (es) 2005-07-01
DK1379522T3 (da) 2005-05-30
RU2270197C2 (ru) 2006-02-20
NZ528345A (en) 2005-04-29
HUP0400991A3 (en) 2009-06-29
NO20034496D0 (no) 2003-10-08
NO325300B1 (no) 2008-03-25
AU2002310912B2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
JP4043953B2 (ja) mGluR2アンタゴニストIとしてのジヒドロ−ベンゾ〔b〕〔1,4〕ジアゼピン−2−オン誘導体
EP1379511B1 (en) DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
AU2002310912A1 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I
AU2002312788A1 (en) Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as mGluR2 antagonists II
NO327817B1 (no) ``Benzodiazepin-derivater, deres fremstilling, medikament inneholdende slike samt anvendelse av disse for fremstilling av medikament for behandling av sykdom``
CZ20021663A3 (cs) Nové deriváty benzodiazepinu
RU45093U1 (ru) Пылеуловитель

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071114

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101122

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101122

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111122

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121122

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121122

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131122

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees